<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">Ann Intensive Care</journal-id><journal-title-group><journal-title>Annals of Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2110-5820</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394230</article-id><article-id pub-id-type="pmc">PMC12092871</article-id>
<article-id pub-id-type="publisher-id">1490</article-id><article-id pub-id-type="doi">10.1186/s13613-025-01490-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association of metformin administration after septic shock with short-term and long-term survival in septic shock patients with diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Bo-Yeong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sukyo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Woosik</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Jong-Hak</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Hanjin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Moon</surname><given-names>Sungwoo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6003-2552</contrib-id><name><surname>Ahn</surname><given-names>Sejoong</given-names></name><address><email>sejoongahn@naver.com</email><email>sejoongahn@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04h9pn542</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution>Department of Biomedical Sciences, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02cs2sd33</institution-id><institution-id institution-id-type="GRID">grid.411134.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0474 0479</institution-id><institution>Department of Emergency Medicine, </institution><institution>Korea University Ansan Hospital, </institution></institution-wrap>123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do 15355 Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>68</elocation-id><history><date date-type="received"><day>8</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">In addition to glycemic control, the anti-inflammatory effects and protective effect of metformin on sepsis have been reported in animal studies, which may be beneficial for patients with septic shock. Few observational studies have evaluated metformin administration after sepsis or bacteremia; however, these studies did not specifically analyze septic shock or long-term outcomes. Therefore, this study aimed to evaluate the associations between metformin administration after septic shock and the short- and long-term survival in septic shock patients with type 2 diabetes mellitus.</p></sec><sec><title>Method</title><p id="Par2">This retrospective observational study used data from a prospectively collected sepsis registry. From October 2016 to June 2022, adult septic shock patients with type 2 diabetes mellitus were included in this study. The variable of interest was metformin administration within 48&#x000a0;h after diagnosis of septic shock. The 90-day mortality and 365-day mortality were evaluated as outcomes. A multivariable Cox proportional hazards model was conducted.</p></sec><sec><title>Results</title><p id="Par3">A total of 320 patients were included in the study. Metformin administration within 48&#x000a0;h after diagnosis of septic shock was associated with lower 90-day mortality (13.0% vs. 39.8%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), 365-day mortality (23.3% vs. 48.3%, <italic>P</italic>&#x02009;=&#x02009;0.001), and in-hospital mortality (9.3% vs. 28.6%, <italic>P</italic>&#x02009;=&#x02009;0.002) than those who did not administer metformin within 48&#x000a0;h. Metformin administration within 48&#x000a0;h was independently associated with decreased 90-day mortality (adjusted hazard ratio [aHR]: 0.371, 95% confidence interval [CI]: 0.153&#x02013;0.900, <italic>P</italic>&#x02009;=&#x02009;0.028) and 365-day mortality (aHR 0.453, 95% CI 0.219&#x02013;0.937, <italic>P</italic>&#x02009;=&#x02009;0.033) after adjusting for potential confounders. Similar results were found for metformin administration within 72&#x000a0;h after septic shock (aHR 0.433, 95% CI 0.235&#x02013;0.797, <italic>P</italic>&#x02009;=&#x02009;0.007 for 90-day mortality and aHR 0.450, 95% CI 0.264&#x02013;0.767, <italic>P</italic>&#x02009;=&#x02009;0.003 for 365-day mortality).</p></sec><sec><title>Conclusions</title><p id="Par4">In septic shock patients with type 2 diabetes mellitus, metformin administration within 48&#x000a0;h was associated with lower 90-day and 365-day mortality. While these findings suggest potential benefits of metformin administration after septic shock, further large, multicenter studies are warranted.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13613-025-01490-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Septic shock</kwd><kwd>Type 2 diabetes mellitus</kwd><kwd>Metformin</kwd><kwd>Diabetic medication</kwd><kwd>Biguanide</kwd><kwd>Survival</kwd></kwd-group><funding-group><award-group><funding-source><institution>Korea University Ansan Hospital</institution></funding-source><award-id>O2411351, O2412011, O2513281</award-id><principal-award-recipient><name><surname>Ahn</surname><given-names>Sejoong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; La Soci&#x000e9;t&#x000e9; de R&#x000e9;animation de Langue Francaise = The French Society of Intensive Care (SRLF) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par14">Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and is a major global burden with high mortality [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Septic shock is the most severe form of sepsis, with a mortality rate of approximately 38% [<xref ref-type="bibr" rid="CR2">2</xref>]. Comprehensive management of patients is required to reduce the high mortality due to septic shock [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par15">The prevalence of diabetes mellitus in 2019 was estimated to be 463&#x000a0;million and is expected to increase globally [<xref ref-type="bibr" rid="CR4">4</xref>]. Diabetes mellitus is a well-known risk factor for cardiovascular diseases and is associated with a high rate of mortality in various diseases [<xref ref-type="bibr" rid="CR5">5</xref>]. Diabetes mellitus is associated with an increased risk of infection, higher sepsis-related mortality, and higher rate of colonization by resistant pathogens [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par16">Metformin is a well-known first-line medication for type 2 diabetes mellitus [<xref ref-type="bibr" rid="CR7">7</xref>]. Previous studies have reported that metformin is associated with reduced mortality in patients with diabetes mellitus in various conditions or diseases [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. In addition to glycemic control, metformin has an anti-inflammatory effect and a protective effect in sepsis in animal studies [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. The protective effects of metformin in sepsis have been observed not only in prophylactic but also in post-insult administration in various animal models. These effects have been reported in the heart, nervous system, liver, and other organs [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par17">Metformin can be administered before sepsis or after sepsis during hospitalization. Most previous observational studies have evaluated pre-admission or pre-morbid metformin administration and mortality in sepsis [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. However, observational studies to evaluate metformin administration after sepsis during hospitalization [<xref ref-type="bibr" rid="CR26">26</xref>] or during bacteremia [<xref ref-type="bibr" rid="CR27">27</xref>] are limited. Further those studies did not specifically analyze the effects of metformin administration on septic shock and its long-term outcomes. Therefore, this study aimed to evaluate the association between metformin administration after septic shock and the short- and long-term survival in septic shock patients with type 2 diabetes mellitus. We hypothesized that metformin administration after septic shock is associated with reduced short- and long-term mortality in patients with septic shock and type 2 diabetes mellitus.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par18">This retrospective observational study used data from a prospectively collected sepsis registry. This study was conducted at Korea University Ansan Hospital, the only tertiary academic teaching hospital in Ansan-si with 700,000 residents [<xref ref-type="bibr" rid="CR10">10</xref>]. The Korea University Ansan Hospital has 880 beds, including 44 intensive care unit beds. The study was conducted in accordance with the principles of the Declaration of Helsinki. This study was approved by the Institutional Review Board of Korea University Ansan Hospital (2022AS0266). The requirement for informed consent was waived by the Institutional Review Board owing to the observational design of this study.</p></sec><sec id="Sec4"><title>Study population</title><p id="Par19">Adult patients (age&#x02009;&#x0003e;&#x02009;18 years) with type 2 diabetes mellitus who were diagnosed with septic shock on the day of hospital admission between October 2016 and June 2022 were included in this study. Patients with a do-not-resuscitate (DNR) order, patients with chronic kidney disease, and those whose 90-day mortality data were unavailable due to loss to follow-up were excluded. Patients who survived for &#x0003c;&#x02009;48&#x000a0;h were excluded because metformin administration within 48&#x000a0;h would not be possible and including data of those patients might result in survival bias.</p></sec><sec id="Sec5"><title>Definitions and data collection</title><p id="Par20">Sepsis was defined as an acute increase from baseline in total sequential organ failure assessment (SOFA) score&#x02009;&#x02265;&#x02009;2 due to infection [<xref ref-type="bibr" rid="CR1">1</xref>]. Septic shock was defined as a serum lactate level&#x02009;&#x0003e;&#x02009;2 mmol/L and the requirement of vasopressors despite adequate fluid resuscitation to maintain a mean arterial pressure&#x02009;&#x02265;&#x02009;65 mmHg. All patients were managed according to the Surviving Sepsis Campaign guidelines [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par21">The variable of interest was metformin administration within 48&#x000a0;h after diagnosis of septic shock. The other variables evaluated were other diabetic medications within 48&#x000a0;h, and metformin administration within 72&#x000a0;h (3 days) after diagnosis of septic shock. Since alpha-glucosidase (<italic>n</italic>&#x02009;=&#x02009;1), incretin (<italic>n</italic>&#x02009;=&#x02009;0), meglitinides (<italic>n</italic>&#x02009;=&#x02009;1), sodium glucose cotransporter 2 (SGLT2) inhibitors (<italic>n</italic>&#x02009;=&#x02009;0), and thiazolidinedione (<italic>n</italic>&#x02009;=&#x02009;3) were administered to only a few patients, hence we evaluated only sulfonylureas, dipeptidyl peptidase 4 (DPP4) inhibitors, and insulin as other diabetic medications. Diabetic medications administration within 48&#x000a0;h after septic shock was confirmed using electronic medical records recorded by the physicians and nurses.</p><p id="Par22">Acute kidney injury (AKI) was defined according to the Kidney Disease Improving Global Outcomes guidelines as stages 1&#x02013;3 [<xref ref-type="bibr" rid="CR28">28</xref>]. High-dose vasopressor was defined as the requirement of norepinephrine-equivalent dose&#x02009;&#x02265;&#x02009;0.25&#x000a0;&#x000b5;g/kg/min. Low-dose vasopressor was defined as the requirement of norepinephrine-equivalent dose&#x02009;&#x0003c;&#x02009;0.1&#x000a0;&#x000b5;g/kg/min. Cardiovascular instability was defined either requirement of high-dose vasopressor, low cardiac output, or poor lactate clearance.</p><p id="Par23">The following patient data were extracted from the electronic medical records: age, sex, preadmission diabetes medication, diabetes medication, comorbidities, age-adjusted Charlson Comorbidity Index [<xref ref-type="bibr" rid="CR29">29</xref>], SOFA score, initial vital signs, clinical data, initial and serial laboratory results, and survival outcomes.</p></sec><sec id="Sec6"><title>Outcomes</title><p id="Par24">The primary outcome was 90-day mortality. The secondary outcome was 365-day mortality.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par25">Continuous variables with normal distribution are presented as means and standard deviations and compared using the Student&#x02019;s t-test. Continuous variables without normal distributions are presented as medians and interquartile ranges (IQRs), and compared using the Mann-Whitney U test. Categorical variables are expressed as numbers and percentages and compared using the chi-square test or Fisher&#x02019;s exact test.</p><p id="Par26">To evaluate the independent association between metformin administration and outcome variables, a multivariable Cox proportional hazards model was used. Variables with a p-value&#x02009;&#x0003c;&#x02009;0.1 in the univariable Cox proportional hazard model (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>) and well-known risk factors (based on previous studies) were entered into the multivariable Cox proportional hazard model. Kaplan-Meier analysis and log-rank tests were conducted.</p><p id="Par27">Subgroup analyses were performed according to preadmission metformin administration, metformin dose, lactate level, AKI, and low-dose vasopressor at 48&#x000a0;h. Sensitivity analysis was performed after multiple imputations using Multivariate Imputation by Chained Equations (&#x02018;mice&#x02019; package) for cases with missing outcomes. Another sensitivity analysis was conducted after including patients with chronic kidney disease.</p><p id="Par28">Statistical significance was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. All statistical analyses were performed using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par29">Between October 2016 and June 2022, 458 patients with septic shock and type 2 diabetes mellitus were screened. Of the screened patients, 18 patients who had a DNR order, 15 patients who survived&#x02009;&#x0003c;&#x02009;48&#x000a0;h, 37 patients who had unknown 90-day mortality, and 68 patients with chronic kidney disease were excluded. Finally, a total of 320 patients were included in the analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Mean age of the study population was 72.1&#x02009;&#x000b1;&#x02009;11.6, and mean SOFA score was 9.3&#x02009;&#x000b1;&#x02009;2.7, and 50.9% of the cohort comprised of men and 49.1% of women. The 90-day mortality rate was 35.3% (113/320), and 365-day mortality rate was 44.5% (126/283), respectively.</p><p id="Par30">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of study population</p></caption><graphic xlink:href="13613_2025_1490_Fig1_HTML" id="d33e431"/></fig>
</p><p id="Par31">Baseline characteristics according to 90-day mortality are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Age, initial SOFA score, age-adjusted Charlson Comorbidity Index, respiratory rate, and lactate were significantly higher in the non-surviving group than surviving group. Infection focus as respiratory origin, malignancy, cardiovascular instability, high-dose vasopressor, low cardiac output, poor lactate clearance, and glucose intolerance requiring insulin were significantly more frequent in the non-surviving group than surviving group. Low or zero-dose vasopressor at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h were significantly more frequent in the surviving group than non-surviving group. Among diabetic medications after septic shock, metformin within 48&#x000a0;h and metformin within 72&#x000a0;h were more frequently administered in the surviving group than non-surviving group (22.7% vs. 6.2%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 and 47.8% vs. 15.9%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, respectively), whereas insulin within 48&#x000a0;h was less frequently administered in the surviving group than non-surviving group. Baseline characteristics according to 365-day mortality (<italic>n</italic>&#x02009;=&#x02009;283) are shown in Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>.</p><p id="Par32">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics according to 90-day mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Survived at day 90<break/>(<italic>N</italic>&#x02009;=&#x02009;207)</th><th align="left">Died at day 90<break/>(<italic>N</italic>&#x02009;=&#x02009;113)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left">0.474</td></tr><tr><td align="left">&#x02003;Men</td><td align="left">109 (52.7%)</td><td align="left">54 (47.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Women</td><td align="left">98 (47.3%)</td><td align="left">59 (52.2%)</td><td align="left"/></tr><tr><td align="left">Age (years)</td><td align="left">73 [62&#x02013;80]</td><td align="left">76 [67&#x02013;81]</td><td align="left">0.042</td></tr><tr><td align="left">Initial SOFA score</td><td align="left">8 [7&#x02013;10]</td><td align="left">11 [8&#x02013;12]</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Infection focus</bold>
</td><td align="left"/><td align="left"/><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Respiratory</td><td align="left">63 (30.4%)</td><td align="left">61 (54.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Gastrointestinal</td><td align="left">27 (13.0%)</td><td align="left">10 (8.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Biliary-pancreas</td><td align="left">37 (17.9%)</td><td align="left">11 (9.7%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Genitourinary</td><td align="left">73 (35.3%)</td><td align="left">23 (20.4%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others</td><td align="left">7 (3.4%)</td><td align="left">8 (7.1%)</td><td align="left"/></tr><tr><td align="left">
<bold>Comorbidities</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Age-adjusted Charlson Comorbidity Index</td><td align="left">4.6&#x02009;&#x000b1;&#x02009;1.8</td><td align="left">5.3&#x02009;&#x000b1;&#x02009;1.7</td><td align="left">0.001</td></tr><tr><td align="left">Hypertension</td><td align="left">152 (73.4%)</td><td align="left">77 (68.1%)</td><td align="left">0.383</td></tr><tr><td align="left">Heart Disease</td><td align="left">29 (14.0%)</td><td align="left">17 (15.0%)</td><td align="left">0.932</td></tr><tr><td align="left">Liver Disease</td><td align="left">14 (6.8%)</td><td align="left">10 (8.8%)</td><td align="left">0.649</td></tr><tr><td align="left">Chronic Lung Disease</td><td align="left">7 (3.4%)</td><td align="left">7 (6.2%)</td><td align="left">0.374</td></tr><tr><td align="left">Stroke</td><td align="left">43 (20.8%)</td><td align="left">26 (23.0%)</td><td align="left">0.747</td></tr><tr><td align="left">Malignancy</td><td align="left">32 (15.5%)</td><td align="left">34 (30.1%)</td><td align="left">0.003</td></tr><tr><td align="left">
<bold>Preadmission Diabetic Medications</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Metformin</td><td align="left">86 (41.5%)</td><td align="left">34 (30.1%)</td><td align="left">0.057</td></tr><tr><td align="left">Sulfonylurea</td><td align="left">43 (20.8%)</td><td align="left">20 (17.7%)</td><td align="left">0.607</td></tr><tr><td align="left">DPP4 inhibitor</td><td align="left">63 (30.4%)</td><td align="left">31 (27.4%)</td><td align="left">0.664</td></tr><tr><td align="left">Insulin</td><td align="left">15 (7.2%)</td><td align="left">5 (4.4%)</td><td align="left">0.450</td></tr><tr><td align="left">Alpha-glucosidase</td><td align="left">4 (1.9%)</td><td align="left">1 (0.9%)</td><td align="left">0.802</td></tr><tr><td align="left">Incretin</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Meglitinides</td><td align="left">0 (0.0%)</td><td align="left">2 (1.8%)</td><td align="left">0.239</td></tr><tr><td align="left">SGLT2 inhibitor</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Thiazolidinedione</td><td align="left">6 (2.9%)</td><td align="left">6 (5.3%)</td><td align="left">0.437</td></tr><tr><td align="left">
<bold>Initial Vital Signs</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic Blood Pressure (mmHg)</td><td align="left">108 [89&#x02013;130]</td><td align="left">103 [83.5&#x02013;123]</td><td align="left">0.179</td></tr><tr><td align="left">Diastolic Blood Pressure (mmHg)</td><td align="left">61 [52&#x02013;75]</td><td align="left">60 [53&#x02013;73]</td><td align="left">0.778</td></tr><tr><td align="left">Heart Rate (/min)</td><td align="left">104 [88&#x02013;121]</td><td align="left">110 [98&#x02013;126]</td><td align="left">0.039</td></tr><tr><td align="left">Respiratory Rate (/min)</td><td align="left">20 [18&#x02013;24]</td><td align="left">22 [18&#x02013;27]</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Body Temperature (&#x02103;)</td><td align="left">37.0 [36.5&#x02013;38.0]</td><td align="left">37.0 [36.0&#x02013;37.0]</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Initial Lab</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lactate (mmol/L)</td><td align="left">4.1 [3.1&#x02013;6.4]</td><td align="left">6.6 [3.9&#x02013;10.3]</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Hemoglobin (g/dL)</td><td align="left">11.8&#x02009;&#x000b1;&#x02009;2.5</td><td align="left">10.6&#x02009;&#x000b1;&#x02009;2.5</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">White blood cell (*10<sup>3</sup>/&#x000b5;L)</td><td align="left">10.6 [6.5&#x02013;16.7]</td><td align="left">11.6 [5.4&#x02013;19.5]</td><td align="left">0.633</td></tr><tr><td align="left">Platelet (*10<sup>3</sup>/&#x000b5;L)</td><td align="left">163 [117.5&#x02013;219]</td><td align="left">157 [76&#x02013;274]</td><td align="left">0.862</td></tr><tr><td align="left">Creatinine (mg/dL)</td><td align="left">1.4 [1.0&#x02013;1.9]</td><td align="left">1.4 [0.9&#x02013;2.0]</td><td align="left">0.838</td></tr><tr><td align="left">Total Bilirubin (mg/dL)</td><td align="left">0.8 [0.5&#x02013;1.4]</td><td align="left">0.6 [0.4&#x02013;1.3]</td><td align="left">0.237</td></tr><tr><td align="left">CRP (mg/dL)</td><td align="left">10.1 [3.5&#x02013;19.7]</td><td align="left">11.7 [6.7&#x02013;22.0]</td><td align="left">0.068</td></tr><tr><td align="left">Glucose (mg/dL)</td><td align="left">183 [140.5&#x02013;251.5]</td><td align="left">189 [127&#x02013;264]</td><td align="left">0.894</td></tr><tr><td align="left">HbA1c (%)*</td><td align="left">7.2 [6.3&#x02013;8.4]</td><td align="left">6.7 [6.0&#x02013;7.6]</td><td align="left">0.079</td></tr><tr><td align="left">
<bold>Initial Clinical Data</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Acute kidney injury (any stage)</td><td align="left">128 (61.8%)</td><td align="left">66 (58.4%)</td><td align="left">0.631</td></tr><tr><td align="left">Cardiovascular instability (any)</td><td align="left">92 (44.4%)</td><td align="left">79 (69.9%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">High-dose vasopressor (norepinephrine-equivalent dose&#x02009;&#x02265;&#x02009;0.25&#x000a0;&#x000b5;g/kg/min)</td><td align="left">62 (30.0%)</td><td align="left">69 (61.1%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">&#x02003;Low cardiac output</td><td align="left">39 (18.8%)</td><td align="left">37 (32.7%)</td><td align="left">0.008</td></tr><tr><td align="left">&#x02003;Poor lactate clearance</td><td align="left">17 (8.2%)</td><td align="left">27 (23.9%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Glucose intolerance requiring insulin</td><td align="left">43 (20.8%)</td><td align="left">42 (37.2%)</td><td align="left">0.001</td></tr><tr><td align="left">Large aspiration</td><td align="left">20 (9.7%)</td><td align="left">11 (9.7%)</td><td align="left">1.000</td></tr><tr><td align="left">
<bold>Serial Clinical Data</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Low or zero-dose vasopressor at 48&#x000a0;h (norepinephrine equivalent dose&#x02009;&#x0003c;&#x02009;0.1&#x000a0;&#x000b5;g/kg/min)</td><td align="left">164 (79.2%)</td><td align="left">41 (36.3%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Glucose intolerance requiring insulin at 48&#x000a0;h</td><td align="left">42 (20.3%)</td><td align="left">34 (30.1%)</td><td align="left">0.067</td></tr><tr><td align="left">Enteral nutrition at 48&#x000a0;h</td><td align="left">124 (59.9%)</td><td align="left">42 (37.2%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Diabetic Medication After Septic Shock**</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Metformin within 48&#x000a0;h</td><td align="left">47 (22.7%)</td><td align="left">7 (6.2%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Metformin within 72&#x000a0;h</td><td align="left">99 (47.8%)</td><td align="left">18 (15.9%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Sulfonylurea within 48&#x000a0;h</td><td align="left">10 (4.8%)</td><td align="left">4 (3.5%)</td><td align="left">0.800</td></tr><tr><td align="left">DPP4 inhibitor within 48&#x000a0;h</td><td align="left">28 (13.5%)</td><td align="left">8 (7.1%)</td><td align="left">0.119</td></tr><tr><td align="left">Insulin within 48&#x000a0;h</td><td align="left">94 (45.4%)</td><td align="left">68 (60.2%)</td><td align="left">0.016</td></tr><tr><td align="left">Alpha-glucosidase within 48&#x000a0;h</td><td align="left">1 (0.5%)</td><td align="left">0 (0.0%)</td><td align="left">1.000</td></tr><tr><td align="left">Incretin within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Meglitinides within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">1 (0.9%)</td><td align="left">0.758</td></tr><tr><td align="left">SGLT2 inhibitor within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Thiazolidinedione within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">1 (0.9%)</td><td align="left">0.758</td></tr></tbody></table><table-wrap-foot><p>Data are presented as median [interquartile range], mean&#x02009;&#x000b1;&#x02009;standard deviation, or number (%), as appropriate</p><p>Abbreviations: SOFA, sequential organ failure assessment; CRP, C-reactive protein; DPP4, dipeptidyl peptidase 4; SGLT2, sodium glucose cotransporter 2</p><p>*<italic>N</italic>&#x02009;=&#x02009;176</p><p>**Diabetic medication within 48&#x000a0;h after septic shock, except metformin within 72&#x000a0;h</p></table-wrap-foot></table-wrap>
</p><p id="Par33">The baseline characteristics according to metformin administration within 48&#x000a0;h are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Initial SOFA score was significantly lower in metformin administration within 48&#x000a0;h group than no metformin group. Preadmission metformin was more frequently used in metformin administration within 48&#x000a0;h group than no metformin group. Age, sex, age-adjusted Charlson Comorbidity Index, initial vital signs (except for body temperature), lactate, creatinine, CRP, and HbA1c were not significantly different between the groups. Lactate and creatinine on hospital day 2 and 3, cardiovascular instability, high-dose vasopressor, low cardiac output, poor lactate clearance, glucose intolerance requiring insulin, and large aspiration were not significantly different between the groups. Low or zero-dose vasopressor at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h were significantly more frequent in metformin administration within 48&#x000a0;h group than no metformin group. Among the diabetic medications after septic shock, sulfonylureas within 48&#x000a0;h and DPP4 inhibitors within 48&#x000a0;h were more frequently administered in metformin administration within 48&#x000a0;h group than no metformin group. The 90-day mortality (13.0% vs. 39.8%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), 365-day mortality (23.3% vs. 48.3%, <italic>P</italic>&#x02009;=&#x02009;0.001), and in-hospital mortality (9.3% vs. 28.6%, <italic>P</italic>&#x02009;=&#x02009;0.002) were significantly lower in metformin administration within 48&#x000a0;h group than no metformin group.</p><p id="Par34">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline characteristics according to Metformin administration within 48&#x000a0;h</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">No metformin administration within 48&#x000a0;h<break/>(<italic>N</italic>&#x02009;=&#x02009;266)</th><th align="left">Metformin administration within 48&#x000a0;h<break/>(<italic>N</italic>&#x02009;=&#x02009;54)</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left">0.232</td></tr><tr><td align="left">&#x02003;Men</td><td align="left">140 (52.6%)</td><td align="left">23 (42.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Women</td><td align="left">126 (47.4%)</td><td align="left">31 (57.4%)</td><td align="left"/></tr><tr><td align="left">Age (years)</td><td align="left">75 [63&#x02013;80]</td><td align="left">75.5 [67&#x02013;82]</td><td align="left">0.514</td></tr><tr><td align="left">Initial SOFA score</td><td align="left">9 [8&#x02013;11]</td><td align="left">8 [7&#x02013;10]</td><td align="left">0.004</td></tr><tr><td align="left">
<bold>Infection focus</bold>
</td><td align="left"/><td align="left"/><td align="left">0.068</td></tr><tr><td align="left">&#x02003;Respiratory</td><td align="left">109 (41.0%)</td><td align="left">15 (27.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Gastrointestinal</td><td align="left">30 (11.3%)</td><td align="left">7 (13.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Biliary-pancreas</td><td align="left">39 (14.7%)</td><td align="left">9 (16.7%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Genitourinary</td><td align="left">73 (27.4%)</td><td align="left">23 (42.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others</td><td align="left">15 (5.6%)</td><td align="left">0 (0.0%)</td><td align="left"/></tr><tr><td align="left">
<bold>Comorbidities</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Age-adjusted Charlson Comorbidity Index</td><td align="left">4.8&#x02009;&#x000b1;&#x02009;1.8</td><td align="left">5.1&#x02009;&#x000b1;&#x02009;1.9</td><td align="left">0.254</td></tr><tr><td align="left">Hypertension</td><td align="left">191 (71.8%)</td><td align="left">38 (70.4%)</td><td align="left">0.962</td></tr><tr><td align="left">Heart Disease</td><td align="left">38 (14.3%)</td><td align="left">8 (14.8%)</td><td align="left">1.000</td></tr><tr><td align="left">Liver Disease</td><td align="left">19 (7.1%)</td><td align="left">5 (9.3%)</td><td align="left">0.799</td></tr><tr><td align="left">Chronic Lung Disease</td><td align="left">13 (4.9%)</td><td align="left">1 (1.9%)</td><td align="left">0.529</td></tr><tr><td align="left">Stroke</td><td align="left">58 (21.8%)</td><td align="left">11 (20.4%)</td><td align="left">0.958</td></tr><tr><td align="left">Malignancy</td><td align="left">53 (19.9%)</td><td align="left">13 (24.1%)</td><td align="left">0.615</td></tr><tr><td align="left">
<bold>Preadmission Diabetic Medications</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Metformin</td><td align="left">87 (32.7%)</td><td align="left">33 (61.1%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Sulfonylurea</td><td align="left">51 (19.2%)</td><td align="left">12 (22.2%)</td><td align="left">0.744</td></tr><tr><td align="left">DPP4 inhibitor</td><td align="left">72 (27.1%)</td><td align="left">22 (40.7%)</td><td align="left">0.065</td></tr><tr><td align="left">Insulin</td><td align="left">17 (6.4%)</td><td align="left">3 (5.6%)</td><td align="left">1.000</td></tr><tr><td align="left">Alpha-glucosidase</td><td align="left">5 (1.9%)</td><td align="left">0 (0.0%)</td><td align="left">0.679</td></tr><tr><td align="left">Incretin</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Meglitinides</td><td align="left">1 (0.4%)</td><td align="left">1 (1.9%)</td><td align="left">0.758</td></tr><tr><td align="left">SGLT2 inhibitor</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Thiazolidinedione</td><td align="left">10 (3.8%)</td><td align="left">2 (3.7%)</td><td align="left">1.000</td></tr><tr><td align="left">
<bold>Initial Vital Signs</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic Blood Pressure (mmHg)</td><td align="left">105 [84&#x02013;123]</td><td align="left">109.5 [92&#x02013;135]</td><td align="left">0.122</td></tr><tr><td align="left">Diastolic Blood Pressure (mmHg)</td><td align="left">60 [52&#x02013;73]</td><td align="left">63.5 [54&#x02013;77]</td><td align="left">0.198</td></tr><tr><td align="left">Heart Rate (/min)</td><td align="left">106 [90&#x02013;123]</td><td align="left">104 [89&#x02013;121]</td><td align="left">0.599</td></tr><tr><td align="left">Respiratory Rate (/min)</td><td align="left">20 [18&#x02013;24]</td><td align="left">20 [18&#x02013;22]</td><td align="left">0.150</td></tr><tr><td align="left">Body Temperature (&#x02103;)</td><td align="left">37.0 [36.0&#x02013;38.0]</td><td align="left">37.5 [37.0&#x02013;38.0]</td><td align="left">0.021</td></tr><tr><td align="left">
<bold>Initial Lab</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lactate (mmol/L)</td><td align="left">4.8 [3.2&#x02013;8.0]</td><td align="left">3.7 [3.1&#x02013;5.9]</td><td align="left">0.051</td></tr><tr><td align="left">Hemoglobin (g/dL)</td><td align="left">11.4&#x02009;&#x000b1;&#x02009;2.6</td><td align="left">11.0&#x02009;&#x000b1;&#x02009;2.2</td><td align="left">0.270</td></tr><tr><td align="left">White blood cell (*10<sup>3</sup>/&#x000b5;L)</td><td align="left">11.2 [6.2&#x02013;19.0]</td><td align="left">9.7 [5.1&#x02013;13.3]</td><td align="left">0.150</td></tr><tr><td align="left">Platelet (*10<sup>3</sup>/&#x000b5;L)</td><td align="left">159.5 [104&#x02013;235]</td><td align="left">174 [119&#x02013;242]</td><td align="left">0.442</td></tr><tr><td align="left">Creatinine (mg/dL)</td><td align="left">1.4 [1.0&#x02013;2.0]</td><td align="left">1.4 [0.9&#x02013;1.6]</td><td align="left">0.073</td></tr><tr><td align="left">Total Bilirubin (mg/dL)</td><td align="left">0.7 [0.4&#x02013;1.3]</td><td align="left">0.6 [0.4&#x02013;1.5]</td><td align="left">0.413</td></tr><tr><td align="left">CRP (mg/dL)</td><td align="left">10.9 [4.6&#x02013;20.9]</td><td align="left">10.3 [3.8&#x02013;17.3]</td><td align="left">0.534</td></tr><tr><td align="left">Glucose (mg/dL)</td><td align="left">186.5 [130&#x02013;262]</td><td align="left">182 [156&#x02013;241]</td><td align="left">0.843</td></tr><tr><td align="left">HbA1c (%)*</td><td align="left">7.0 [6.2&#x02013;8.1]</td><td align="left">7.0 [6.3&#x02013;8.2]</td><td align="left">0.879</td></tr><tr><td align="left">
<bold>Serial Lab</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Hospital day 2**</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Lactate (mmol/L)</td><td align="left">2.6 [1.7&#x02013;4.5]</td><td align="left">2.2 [1.3&#x02013;2.8]</td><td align="left">0.059</td></tr><tr><td align="left">&#x02003;Creatinine (mg/dL)</td><td align="left">1.2 [0.8&#x02013;2.0]</td><td align="left">1.1 [0.8&#x02013;1.4]</td><td align="left">0.100</td></tr><tr><td align="left">&#x02003;Hospital day 3***</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Lactate (mmol/L)</td><td align="left">2.4 [1.5&#x02013;5.2]</td><td align="left">1.7 [1.2&#x02013;2.1]</td><td align="left">0.107</td></tr><tr><td align="left">Creatinine (mg/dL)</td><td align="left">1.1 [0.7&#x02013;1.9]</td><td align="left">0.9 [0.6&#x02013;1.1]</td><td align="left">0.079</td></tr><tr><td align="left">
<bold>Initial Clinical Data</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Acute kidney injury (any stage)</td><td align="left">163 (61.3%)</td><td align="left">31 (57.4%)</td><td align="left">0.705</td></tr><tr><td align="left">Cardiovascular instability (any)</td><td align="left">139 (52.3%)</td><td align="left">32 (59.3%)</td><td align="left">0.429</td></tr><tr><td align="left">High-dose vasopressor (norepinephrine-equivalent dose&#x02009;&#x02265;&#x02009;0.25&#x000a0;&#x000b5;g/kg/min)</td><td align="left">110 (41.4%)</td><td align="left">21 (38.9%)</td><td align="left">0.854</td></tr><tr><td align="left">&#x02003;Low cardiac output</td><td align="left">64 (24.1%)</td><td align="left">12 (22.2%)</td><td align="left">0.909</td></tr><tr><td align="left">&#x02003;Poor lactate clearance</td><td align="left">37 (13.9%)</td><td align="left">7 (13.0%)</td><td align="left">1.000</td></tr><tr><td align="left">Glucose intolerance requiring insulin</td><td align="left">72 (27.1%)</td><td align="left">13 (24.1%)</td><td align="left">0.776</td></tr><tr><td align="left">Large aspiration</td><td align="left">26 (9.8%)</td><td align="left">5 (9.3%)</td><td align="left">1.000</td></tr><tr><td align="left">
<bold>Serial Clinical Data</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Low or zero-dose vasopressor at 48&#x000a0;h (norepinephrine equivalent dose&#x02009;&#x0003c;&#x02009;0.1&#x000a0;&#x000b5;g/kg/min)</td><td align="left">162 (60.9%)</td><td align="left">43 (79.6%)</td><td align="left">0.014</td></tr><tr><td align="left">Glucose intolerance requiring insulin at 48&#x000a0;h</td><td align="left">68 (25.6%)</td><td align="left">8 (14.8%)</td><td align="left">0.129</td></tr><tr><td align="left">Enteral nutrition at 48&#x000a0;h</td><td align="left">125 (47.0%)</td><td align="left">41 (75.9%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Other Diabetic Medication after septic shock</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Sulfonylurea within 48&#x000a0;h</td><td align="left">8 (3.0%)</td><td align="left">6 (11.1%)</td><td align="left">0.022</td></tr><tr><td align="left">DPP4 inhibitor within 48&#x000a0;h</td><td align="left">12 (4.5%)</td><td align="left">24 (44.4%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Insulin within 48&#x000a0;h</td><td align="left">137 (51.5%)</td><td align="left">25 (46.3%)</td><td align="left">0.583</td></tr><tr><td align="left">Alpha-glucosidase within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">1 (1.9%)</td><td align="left">0.376</td></tr><tr><td align="left">Incretin within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Meglitinides within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">1 (1.9%)</td><td align="left">0.376</td></tr><tr><td align="left">SGLT2 inhibitor within 48&#x000a0;h</td><td align="left">0 (0.0%)</td><td align="left">0 (0.0%)</td><td align="left">NA</td></tr><tr><td align="left">Thiazolidinedione within 48&#x000a0;h</td><td align="left">1 (0.4%)</td><td align="left">0 (0.0%)</td><td align="left">1.000</td></tr><tr><td align="left">
<bold>Outcome</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">In-hospital mortality</td><td align="left">76 (28.6%)</td><td align="left">5 (9.3%)</td><td align="left">0.005</td></tr><tr><td align="left">90-day mortality</td><td align="left">106 (39.8%)</td><td align="left">7 (13.0%)</td><td align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">365-day mortality****</td><td align="left">116 (48.3%)</td><td align="left">10 (23.3%)</td><td align="left">0.004</td></tr></tbody></table><table-wrap-foot><p>Data are presented as median [interquartile range], mean&#x02009;&#x000b1;&#x02009;standard deviation, or number (%), as appropriate</p><p>Abbreviations: SOFA, sequential organ failure assessment; CRP, C-reactive protein; DPP4, dipeptidyl peptidase 4; SGLT2, sodium glucose cotransporter 2</p><p>*<italic>N</italic>&#x02009;=&#x02009;176</p><p>**<italic>N</italic>&#x02009;=&#x02009;199 for lactate and <italic>N</italic>&#x02009;=&#x02009;309 for creatinine</p><p>***<italic>N</italic>&#x02009;=&#x02009;125 for lactate and <italic>N</italic>&#x02009;=&#x02009;278 for creatinine</p><p>****<italic>N</italic>&#x02009;=&#x02009;283</p></table-wrap-foot></table-wrap>
</p><sec id="Sec9"><title>Multivariable Cox proportional hazard model</title><p id="Par35">Administration of metformin within 48&#x000a0;h was independently associated with decreased 90-day mortality after adjustment of sex, initial SOFA score, infection focus, age-adjusted Charlson Comorbidity Index, preadmission metformin, vital signs, lactate, hemoglobin, sulfonylurea, DPP4 inhibitor, insulin, high-dose vasopressor, low cardiac output, poor lactate clearance, glucose intolerance requiring insulin, large aspiration, low or zero-dose vasopressor at 48&#x000a0;h, glucose intolerance requiring insulin at 48&#x000a0;h, and enteral nutrition at 48&#x000a0;h (adjusted hazard ratio [aHR]: 0.371, 95% confidence interval [CI]: 0.153&#x02013;0.900, <italic>P</italic>&#x02009;=&#x02009;0.028; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>). Administration of metformin within 48&#x000a0;h was also independently associated with 90-day mortality in other models (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Administration of metformin within 48&#x000a0;h was independently associated with decreased 365-day mortality after adjustment (aHR 0.453, 95% CI 0.219&#x02013;0.937, <italic>P</italic>&#x02009;=&#x02009;0.033; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par36">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Multivariable Cox proportional hazard model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">aHR</th><th align="left">95% CI</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">
<bold>90-day mortality</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Metformin within 48&#x000a0;h</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Model 1</td><td char="." align="char">0.371</td><td char="." align="char">0.153&#x02013;0.900</td><td char="." align="char">0.028</td></tr><tr><td align="left">&#x02003;Model 2</td><td char="." align="char">0.361</td><td char="." align="char">0.148&#x02013;0.878</td><td char="." align="char">0.025</td></tr><tr><td align="left">&#x02003;Model 3</td><td char="." align="char">0.340</td><td char="." align="char">0.139&#x02013;0.828</td><td char="." align="char">0.018</td></tr><tr><td align="left">Metformin within 72&#x000a0;h</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Model 1</td><td char="." align="char">0.433</td><td char="." align="char">0.235&#x02013;0.797</td><td char="." align="char">0.007</td></tr><tr><td align="left">&#x02003;Model 2</td><td char="." align="char">0.431</td><td char="." align="char">0.234&#x02013;0.793</td><td char="." align="char">0.007</td></tr><tr><td align="left">&#x02003;Model 3</td><td char="." align="char">0.420</td><td char="." align="char">0.227&#x02013;0.776</td><td char="." align="char">0.006</td></tr><tr><td align="left">
<bold>365-day mortality*</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Metformin within 48&#x000a0;h</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Model 1</td><td char="." align="char">0.453</td><td char="." align="char">0.219&#x02013;0.937</td><td char="." align="char">0.033</td></tr><tr><td align="left">&#x02003;Model 2</td><td char="." align="char">0.477</td><td char="." align="char">0.232&#x02013;0.979</td><td char="." align="char">0.044</td></tr><tr><td align="left">&#x02003;Model 3</td><td char="." align="char">0.468</td><td char="." align="char">0.226&#x02013;0.973</td><td char="." align="char">0.042</td></tr><tr><td align="left">Metformin within 72&#x000a0;h</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Model 1</td><td char="." align="char">0.450</td><td char="." align="char">0.264&#x02013;0.767</td><td char="." align="char">0.003</td></tr><tr><td align="left">&#x02003;Model 2</td><td char="." align="char">0.454</td><td char="." align="char">0.266&#x02013;0.774</td><td char="." align="char">0.004</td></tr><tr><td align="left">&#x02003;Model 3</td><td char="." align="char">0.453</td><td char="." align="char">0.266&#x02013;0.771</td><td char="." align="char">0.004</td></tr></tbody></table><table-wrap-foot><p>*<italic>N</italic>&#x02009;=&#x02009;283</p><p>Model 1: sex, initial SOFA score, infection focus, age-adjusted Charlson Comorbidity Index, preadmission metformin, vital signs, lactate, hemoglobin, sulfonylurea, DPP4 inhibitor, insulin, high-dose vasopressor, low cardiac output, poor lactate clearance, glucose intolerance requiring insulin, large aspiration, low or zero-dose vasopressor at 48&#x000a0;h, glucose intolerance requiring insulin at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h were adjusted</p><p>Model 2: sex, initial SOFA score, infection focus, age-adjusted Charlson Comorbidity Index, preadmission metformin, vital signs, lactate, hemoglobin, sulfonylurea, DPP4 inhibitor, insulin, cardiovascular instability (any), glucose intolerance requiring insulin, large aspiration, low or zero-dose vasopressor at 48&#x000a0;h, glucose intolerance requiring insulin at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h were adjusted</p><p>Model 3: sex, initial SOFA score, infection focus, age-adjusted Charlson Comorbidity Index, preadmission metformin, vital signs, lactate, hemoglobin, sulfonylurea, DPP4 inhibitor, insulin, high-dose vasopressor, low cardiac output, poor lactate clearance, glucose intolerance requiring insulin, large aspiration, AKI, malignancy, low or zero-dose vasopressor at 48&#x000a0;h, glucose intolerance requiring insulin at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h were adjusted</p></table-wrap-foot></table-wrap>
</p><p id="Par37">Administration of metformin within 72&#x000a0;h was independently associated with decreased 90-day mortality after adjustment (aHR 0.433, 95% CI 0.235&#x02013;0.797, <italic>P</italic>&#x02009;=&#x02009;0.007; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Administration of metformin within 72&#x000a0;h was independently associated with decreased 365-day mortality after adjustment (aHR 0.450, 95% CI 0.264&#x02013;0.767, <italic>P</italic>&#x02009;=&#x02009;0.003; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec10"><title>Kaplan-Meier curve</title><p id="Par38">The survival rate was higher in the group with metformin administration within 48&#x000a0;h than no metformin group (log-rank test, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A).</p><p id="Par39">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier curve. Kaplan-Meier curve according to metformin administration within 48&#x000a0;h (<bold>A</bold>). Kaplan-Meier curve in subgroup with no preadmission metformin administration (<bold>B</bold>). Kaplan-Meier curve in subgroup with preadmission metformin administration (<bold>C</bold>)</p></caption><graphic xlink:href="13613_2025_1490_Fig2_HTML" id="d33e2154"/></fig>
</p><p id="Par40">The survival rate was higher in the group with metformin administration within 48&#x000a0;h than no metformin group irrespective of preadmission metformin administration (log-rank test, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B and C).</p></sec><sec id="Sec11"><title>Analysis according to administered metformin dose</title><p id="Par41">The 90-day mortality and 365-day mortality rates were lowest in the group with metformin administration of 500&#x02013;1000&#x000a0;mg/day (both <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01; Supplementary Table <xref rid="MOESM1" ref-type="media">4</xref>).</p><p id="Par42">Administration of metformin 500&#x02013;1000&#x000a0;mg/day was independently associated with decreased 90-day and 365-day mortality after adjusting for the afore-mentioned covariables (aHR 0.311, 95% CI 0.115&#x02013;0.840, <italic>P</italic>&#x02009;=&#x02009;0.021 and aHR 0.384, 95% CI 0.163&#x02013;0.907, <italic>P</italic>&#x02009;=&#x02009;0.029, respectively; Supplementary Table <xref rid="MOESM1" ref-type="media">5</xref>).</p><p id="Par43">In the analysis according to metformin dose, the survival rate was higher in the group with administration of metformin 500&#x02013;1000&#x000a0;mg/day than other groups (log-rank test, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>).</p></sec><sec id="Sec12"><title>Subgroup analysis</title><p id="Par44">The 90-day mortality was significantly lower in group with metformin administration within 48&#x000a0;h than no metformin group, in subgroup with AKI, in subgroup with low-dose vasopressor at 48&#x000a0;h, and irrespective of the lactate level (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; Supplementary Table <xref rid="MOESM1" ref-type="media">6</xref>).</p></sec><sec id="Sec13"><title>Sensitivity analysis</title><p id="Par45">In the sensitivity analysis after multiple imputations for missing outcomes, metformin administration within 48&#x000a0;h and 72&#x000a0;h were independently associated with decreased 90-day mortality after adjustment for the afore-mentioned covariables (aHR 0.396, 95% CI 0.171&#x02013;0.916, <italic>P</italic>&#x02009;=&#x02009;0.031 and aHR 0.461, 95% CI 0.261&#x02013;0.815, <italic>P</italic>&#x02009;=&#x02009;0.008, respectively).</p><p id="Par46">In the sensitivity analysis after including patients with chronic kidney disease, metformin administration within 48&#x000a0;h and 72&#x000a0;h were independently associated with decreased 90-day mortality after adjustment for the afore-mentioned covariables (aHR 0.398, 95% CI 0.179&#x02013;0.885, <italic>P</italic>&#x02009;=&#x02009;0.023 and aHR 0.507, 95% CI 0.295&#x02013;0.873, <italic>P</italic>&#x02009;=&#x02009;0.014, respectively).</p></sec></sec><sec id="Sec14"><title>Discussions</title><p id="Par47">In septic shock patients with type 2 diabetes mellitus, the administration of metformin within 48&#x000a0;h and 72&#x000a0;h after septic shock was independently associated with decreased 90-day and 365-day mortality. Metformin administration was associated with decreased 90-day irrespective of preadmission metformin administration and lactate level. The results of the sensitivity analysis were similar to the main results.</p><p id="Par48">Most previous studies that reported decreased mortality in sepsis patients who were administered metformin had only evaluated pre-admission or pre-morbid metformin administration and did not evaluate metformin administration after sepsis [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Only a few studies have evaluated the association between administration of metformin after sepsis or bacteremia and mortality [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Previous studies have reported that administration of metformin after sepsis or bacteremia is significantly associated with reduced short-term mortality, which is consistent with our findings. However, those studies evaluated metformin exposure any time during hospitalization for sepsis [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. In addition, previous studies did not specifically evaluate for septic shock, did not adjust for variables that are associated with metformin administration or patients&#x02019; severity, and did not assess long-term outcomes [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Compliance with administering metformin and the time lapse after septic shock may have a significant impact on the results. However, these factors have not yet been sufficiently investigated.</p><p id="Par49">The strengths of our study are that we evaluated the administration of metformin, preadmission diabetic medications, and the time lapse after septic shock more precisely using electronic medical record data and reduced the issue of patient compliance. Furthermore, we adjusted for numerous variables related to metformin use and patient severity. We also excluded patients who survived for less than 48&#x000a0;h to reduce survival bias and evaluated short- and long-term survival outcomes. We conducted a sensitivity analysis and obtained similar findings, which led to robust results. The results of our study provide novel insights into diabetic medications after septic shock, such as diabetes control or potential management of sepsis, and the timing of metformin administration in patients with septic shock and type 2 diabetes mellitus.</p><p id="Par50">The effect of metformin on reducing mortality in patients with sepsis may be attributed to its immunomodulatory properties, as demonstrated in both in vitro and in vivo studies [<xref ref-type="bibr" rid="CR30">30</xref>]. Metformin has been shown to exert protective effects through both AMPK-dependent and AMPK-independent pathways, including the promotion of mitochondrial biogenesis [<xref ref-type="bibr" rid="CR31">31</xref>] and mitophagy [<xref ref-type="bibr" rid="CR32">32</xref>], inhibition of fatty acid synthase [<xref ref-type="bibr" rid="CR33">33</xref>], and suppression of the NLRP3 inflammasome [<xref ref-type="bibr" rid="CR34">34</xref>]. These effects have been reported to influence various immune cell types, including neutrophils, macrophages, and regulatory T cells [<xref ref-type="bibr" rid="CR30">30</xref>]. In animal studies, post-insult metformin administration has been shown to mitigate sepsis-induced injury, with the interval between the insult and metformin administration ranging from 1 to 6&#x000a0;h [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par51">In addition to sepsis or critically ill diseases, metformin has been associated with survival in various cohorts. In obese patients, metformin is associated with reduced mortality [<xref ref-type="bibr" rid="CR8">8</xref>]. Metformin reduces all-cause mortality and major adverse cardiovascular events in patients with coronary artery disease and type 2 diabetes [<xref ref-type="bibr" rid="CR9">9</xref>]. As more major cardiovascular events have been reported in patients with sepsis and diabetes [<xref ref-type="bibr" rid="CR35">35</xref>], the beneficial effects of metformin on major cardiovascular events could have contributed to the additional beneficial effects on long-term outcomes in our study.</p><p id="Par52">As preadmission metformin administration is common in patients with diabetes [<xref ref-type="bibr" rid="CR7">7</xref>] and affects survival outcomes in sepsis [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>], we performed a multivariable analysis adjusting for preadmission metformin administration and conducted a subgroup analysis according to preadmission metformin administration. Both analyses showed beneficial effects of metformin after septic shock, independent of preadmission metformin administration. In animal study that evaluated both prophylactic and post-insult administration of metformin [<xref ref-type="bibr" rid="CR19">19</xref>], prophylactic metformin mitigated sepsis-induced damage, while post-insult metformin significantly improved recovery. Therefore, both preadmission metformin administration and metformin administration after septic shock might be beneficial in patients with septic shock.</p><p id="Par53">Although metformin administration within 48&#x000a0;h and 72&#x000a0;h after septic shock was associated with better outcomes even after adjustment of other diabetic medications such as DPP4 inhibitors, sulfonylurea, and insulin, there might be additional benefits of other diabetic medications. DPP4 inhibitors have been reported to improve vascular dysfunction independently of their role in glucose regulation [<xref ref-type="bibr" rid="CR36">36</xref>]. Additionally, excessive activation of K<sub>ATP</sub> channels in sepsis can lead to hypotension and vascular hypo-responsiveness to catecholamines [<xref ref-type="bibr" rid="CR37">37</xref>]; thus, sulfonylureas, which act as K<sub>ATP</sub> channel blockers, may exert beneficial effects in sepsis. Moreover, given the potential benefits of maintaining well-controlled glycemia in critical illness [<xref ref-type="bibr" rid="CR38">38</xref>], a combination of metformin with other antidiabetic agents may offer additional advantages for patients whose blood glucose levels are not adequately managed with metformin alone. The effects of DPP4 inhibitors and sulfonylurea cannot be discounted and require further studies.</p><p id="Par54">The timing and dose of metformin administration after septic shock may be important. Regarding the timing of metformin in septic shock, we evaluated two timeframes, metformin administration within 48&#x000a0;h and 72&#x000a0;h after septic shock, and found that both were independently associated with reduced short- and long-term mortality. Regarding the dose of metformin in septic shock, the groups with metformin administration of 500&#x02013;1000&#x000a0;mg/day showed lowest mortality. However, the optimal dose cannot be determined in this study, as most patients were administered with 500&#x02013;1000&#x000a0;mg/day metformin and only a small number of patients were administered with more than 1000&#x000a0;mg/day metformin. In fact, all deceased patients who were administered with more than 1000&#x000a0;mg/day metformin developed lactic acidosis after metformin administration. Since metabolism of metformin may be altered in critically ill states, plasma metformin concentration may be an important factor. Given the insufficient evidence to determine optimal dose and timing of metformin administration in patients with septic shock, individual patient conditions should be considered when deciding on the dose and timing of metformin to maximize its beneficial effects, while closely monitoring for metformin toxicity. Further large-cohort or randomized controlled studies are warranted to establish the optimal dose and timing of metformin in patients with septic shock.</p><p id="Par55">This study had several limitations. First, owing to the observational study design, there may be missed covariables. Although we conducted multivariable analysis, the missed covariables might have been unbalanced. In addition, we could only find associations, not causal relationship. Second, the number of included patients was small. The relatively small number of included patients led to a wide 95% CI. Third, the study was conducted at a single center. The results cannot be generalized to the entire population. Further multicenter studies are needed. Fourth, several patients with unknown 90-day outcomes were excluded. However, we conducted sensitivity analysis after multiple imputations and showed similar findings to the main results. Fifth, although we adjusted for other diabetic medications, there may be synergistic effects of other co-administered medications. Sixth, SGLT2 inhibitor was not evaluated because none of the patients were administered SGLT2 inhibitors within 48&#x000a0;h. Further studies are needed to evaluate the effects of SGLT2 inhibitors in patients with sepsis or septic shock. Seventh, metformin administration might indicate an improved clinical condition. To overcome potential selection bias, we excluded patients who survived for less than 48&#x000a0;h. In addition, we adjusted for variables such as cardiovascular instability, high-dose vasopressor, low cardiac output, poor lactate clearance, glucose intolerance requiring insulin, large aspiration, low or zero-dose vasopressor at 48&#x000a0;h, glucose intolerance requiring insulin at 48&#x000a0;h and enteral nutrition at 48&#x000a0;h, all of which are associated with patient severity and metformin use, and found benefits of metformin in patients with septic shock. Furthermore, lactate and creatinine levels on hospital day 2 and 3 were not significantly different between the groups. However, to minimize bias and ensure a balance of characteristics between groups, large-cohort studies or randomized controlled trials are warranted. Eighth, this study included only septic shock patients with type 2 diabetes mellitus. Therefore, the results cannot be generalized to septic shock patients without type 2 diabetes mellitus, warranting further study.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par56">In septic shock patients with type 2 diabetes mellitus, metformin administration within 48&#x000a0;h was associated with lower 90-day and 365-day mortality. While these findings suggest potential benefits of metformin administration after septic shock, further large, multicenter studies are warranted.</p></sec><sec id="Sec16" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13613_2025_1490_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DNR</term><def><p id="Par5">Do-not-resuscitate</p></def></def-item><def-item><term>SOFA</term><def><p id="Par6">Sequential organ failure assessment</p></def></def-item><def-item><term>SGLT2</term><def><p id="Par7">Sodium glucose cotransporter 2</p></def></def-item><def-item><term>DPP4</term><def><p id="Par8">Dipeptidyl peptidase 4</p></def></def-item><def-item><term>AKI</term><def><p id="Par9">Acute kidney injury</p></def></def-item><def-item><term>IQR</term><def><p id="Par10">Interquartile ranges</p></def></def-item><def-item><term>aHR</term><def><p id="Par11">Adjusted hazard ratio</p></def></def-item><def-item><term>CI</term><def><p id="Par12">Confidence interval</p></def></def-item><def-item><term>AMPK</term><def><p id="Par13">Adenosine monophosphate-activated protein kinase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors contributions</title><p>SA and BYJ contributed to study conception and design. SA, BYJ, JHP, HC, and SM contributed to investigation, methodology. SA, BYJ, SL, WK, and SK contributed to data curation, formal analysis and interpretation. SA and BYJ contributed to manuscript drafting. JHP, HC, and SM provided professional suggestions. All authors have made substantial contributions to drafting the article. All authors read and approved the final article.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Korea University Ansan Hospital (O2411351, O2412011, O2513281). This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par57">The Institutional Review Board approved this study (2022AS0266) and waived the requirement for informed consent due to the nature of the study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par58">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par59">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><etal/></person-group><article-title>The third international consensus definitions for Sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>801</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmid">26903338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801&#x02013;10. 10.1001/jama.2016.0287.<pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>David</surname><given-names>S</given-names></name><name><surname>Olariu</surname><given-names>E</given-names></name><name><surname>Cadwell</surname><given-names>KK</given-names></name></person-group><article-title>Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis</article-title><source>Crit Care Lond Engl</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>196</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2478-6</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care Lond Engl. 2019;23(1):196. 10.1186/s13054-019-2478-6.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><etal/></person-group><article-title>Executive summary: surviving Sepsis campaign: international guidelines for the management of Sepsis and septic shock 2021</article-title><source>Crit Care Med</source><year>2021</year><volume>49</volume><issue>11</issue><fpage>1974</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000005357</pub-id><pub-id pub-id-type="pmid">34643578</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Evans L, Rhodes A, Alhazzani W, et al. Executive summary: surviving Sepsis campaign: international guidelines for the management of Sepsis and septic shock 2021. Crit Care Med. 2021;49(11):1974&#x02013;82. 10.1097/CCM.0000000000005357.<pub-id pub-id-type="pmid">34643578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Saeedi</surname><given-names>P</given-names></name><name><surname>Petersohn</surname><given-names>I</given-names></name><name><surname>Salpea</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><fpage>107843</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. 10.1016/j.diabres.2019.107843.<pub-id pub-id-type="pmid">31518657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao Kondapally Seshasai</surname><given-names>S</given-names></name><name><surname>Kaptoge</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diabetes mellitus, fasting glucose, and risk of cause-specific death</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>9</issue><fpage>829</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1008862</pub-id><pub-id pub-id-type="pmid">21366474</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829&#x02013;41. 10.1056/NEJMoa1008862.<pub-id pub-id-type="pmid">21366474</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>E</given-names></name><name><surname>Carlin</surname><given-names>M</given-names></name><name><surname>Porta</surname><given-names>M</given-names></name><name><surname>Brizzi</surname><given-names>MF</given-names></name></person-group><article-title>Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence</article-title><source>Acta Diabetol</source><year>2021</year><volume>58</volume><issue>9</issue><fpage>1139</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s00592-021-01728-4</pub-id><pub-id pub-id-type="pmid">33973089</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Costantini E, Carlin M, Porta M, Brizzi MF. Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence. Acta Diabetol. 2021;58(9):1139&#x02013;51. 10.1007/s00592-021-01728-4.<pub-id pub-id-type="pmid">33973089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Maruthur</surname><given-names>NM</given-names></name><name><surname>Tseng</surname><given-names>E</given-names></name><name><surname>Hutfless</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diabetes medications as monotherapy or Metformin-Based combination therapy for type 2 diabetes: A systematic review and Meta-analysis</article-title><source>Ann Intern Med</source><year>2016</year><volume>164</volume><issue>11</issue><fpage>740</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.7326/M15-2650</pub-id><pub-id pub-id-type="pmid">27088241</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or Metformin-Based combination therapy for type 2 diabetes: A systematic review and Meta-analysis. Ann Intern Med. 2016;164(11):740&#x02013;51. 10.7326/M15-2650.<pub-id pub-id-type="pmid">27088241</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghotbi</surname><given-names>AA</given-names></name><name><surname>K&#x000f8;ber</surname><given-names>L</given-names></name><name><surname>Finer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><issue>11</issue><fpage>3746</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.2337/dc13-0027</pub-id><pub-id pub-id-type="pmid">24089540</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ghotbi AA, K&#x000f8;ber L, Finer N, et al. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care. 2013;36(11):3746&#x02013;53. 10.2337/dc13-0027.<pub-id pub-id-type="pmid">24089540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Monami</surname><given-names>M</given-names></name><name><surname>Candido</surname><given-names>R</given-names></name><name><surname>Pintaudi</surname><given-names>B</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Mannucci</surname><given-names>E</given-names></name><collab>SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes</collab></person-group><article-title>Effect of Metformin on all-cause mortality and major adverse cardiovascular events: an updated meta-analysis of randomized controlled trials</article-title><source>Nutr Metab Cardiovasc Dis NMCD</source><year>2021</year><volume>31</volume><issue>3</issue><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2020.11.031</pub-id><pub-id pub-id-type="pmid">33549430</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Monami M, Candido R, Pintaudi B, Targher G, Mannucci E, SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effect of Metformin on all-cause mortality and major adverse cardiovascular events: an updated meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis NMCD. 2021;31(3):699&#x02013;704. 10.1016/j.numecd.2020.11.031.<pub-id pub-id-type="pmid">33549430</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>BY</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association between Metformin and survival outcomes in in-hospital cardiac arrest patients with diabetes</article-title><source>J Crit Care</source><year>2023</year><volume>73</volume><fpage>154171</fpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2022.154171</pub-id><pub-id pub-id-type="pmid">36279760</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Jin BY, Song J, Kim J, et al. Association between Metformin and survival outcomes in in-hospital cardiac arrest patients with diabetes. J Crit Care. 2023;73:154171. 10.1016/j.jcrc.2022.154171.<pub-id pub-id-type="pmid">36279760</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>JH</given-names></name><collab>METFORMIN MITIGATES SEPSIS-ASSOCIATED PULMONARY FIBROSIS BY PROMOTING AMPK ACTIVATION AND INHIBITING HIF-1&#x003b1;-INDUCED AEROBIC GLYCOLYSIS</collab><etal/></person-group><source>Shock Augusta Ga</source><year>2024</year><volume>61</volume><issue>2</issue><fpage>283</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000002275</pub-id><pub-id pub-id-type="pmid">38010091</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhong H, Tang R, Feng JH, METFORMIN MITIGATES SEPSIS-ASSOCIATED PULMONARY FIBROSIS BY PROMOTING AMPK ACTIVATION AND INHIBITING HIF-1&#x003b1;-INDUCED AEROBIC GLYCOLYSIS, et al. Shock Augusta Ga. 2024;61(2):283&#x02013;93. 10.1097/SHK.0000000000002275.<pub-id pub-id-type="pmid">38010091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><etal/></person-group><article-title>Metformin alleviates Sepsis-Associated myocardial injury by enhancing AMP-Activated protein kinase/mammalian target of Rapamycin signaling Pathway-Mediated autophagy</article-title><source>J Cardiovasc Pharmacol</source><year>2023</year><volume>82</volume><issue>4</issue><fpage>308</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000001463</pub-id><pub-id pub-id-type="pmid">37499052</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gao Y, Liu J, Li K, et al. Metformin alleviates Sepsis-Associated myocardial injury by enhancing AMP-Activated protein kinase/mammalian target of Rapamycin signaling Pathway-Mediated autophagy. J Cardiovasc Pharmacol. 2023;82(4):308&#x02013;17. 10.1097/FJC.0000000000001463.<pub-id pub-id-type="pmid">37499052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protective effect of Metformin on Sepsis myocarditis in zebrafish</article-title><source>Dose-Response Publ Int Hormesis Soc</source><year>2020</year><volume>18</volume><issue>3</issue><fpage>1559325820938543</fpage><pub-id pub-id-type="doi">10.1177/1559325820938543</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zhang M, Sun W, Du J, et al. Protective effect of Metformin on Sepsis myocarditis in zebrafish. Dose-Response Publ Int Hormesis Soc. 2020;18(3):1559325820938543. 10.1177/1559325820938543.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><issue>58</issue><fpage>97977</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20105</pub-id><pub-id pub-id-type="pmid">29228667</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tang G, Yang H, Chen J, et al. Metformin ameliorates sepsis-induced brain injury by inhibiting apoptosis, oxidative stress and neuroinflammation via the PI3K/Akt signaling pathway. Oncotarget. 2017;8(58):97977&#x02013;89. 10.18632/oncotarget.20105.<pub-id pub-id-type="pmid">29228667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Vaez</surname><given-names>H</given-names></name><name><surname>Rameshrad</surname><given-names>M</given-names></name><name><surname>Najafi</surname><given-names>M</given-names></name><name><surname>Barar</surname><given-names>J</given-names></name><name><surname>Barzegari</surname><given-names>A</given-names></name><name><surname>Garjani</surname><given-names>A</given-names></name></person-group><article-title>Cardioprotective effect of Metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart</article-title><source>Eur J Pharmacol</source><year>2016</year><volume>772</volume><fpage>115</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2015.12.030</pub-id><pub-id pub-id-type="pmid">26708162</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Vaez H, Rameshrad M, Najafi M, Barar J, Barzegari A, Garjani A. Cardioprotective effect of Metformin in lipopolysaccharide-induced sepsis via suppression of toll-like receptor 4 (TLR4) in heart. Eur J Pharmacol. 2016;772:115&#x02013;23. 10.1016/j.ejphar.2015.12.030.<pub-id pub-id-type="pmid">26708162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Didari</surname><given-names>T</given-names></name><name><surname>Hassani</surname><given-names>S</given-names></name><name><surname>Baeeri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Short-term effects of Metformin on cardiac and peripheral blood cells following cecal ligation and Puncture-induced Sepsis</article-title><source>Drug Res</source><year>2021</year><volume>71</volume><issue>5</issue><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1055/a-1322-7478</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Didari T, Hassani S, Baeeri M, et al. Short-term effects of Metformin on cardiac and peripheral blood cells following cecal ligation and Puncture-induced Sepsis. Drug Res. 2021;71(5):257&#x02013;64. 10.1055/a-1322-7478.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhai</surname><given-names>R</given-names></name><etal/></person-group><article-title>Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice</article-title><source>Bioengineered</source><year>2022</year><volume>13</volume><issue>2</issue><fpage>4598</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1080/21655979.2022.2036305</pub-id><pub-id pub-id-type="pmid">35156512</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Song H, Zhang X, Zhai R, et al. Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice. Bioengineered. 2022;13(2):4598&#x02013;609. 10.1080/21655979.2022.2036305.<pub-id pub-id-type="pmid">35156512</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metformin attenuated sepsis-related liver injury by modulating gut microbiota</article-title><source>Emerg Microbes Infect</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>815</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2045876</pub-id><pub-id pub-id-type="pmid">35191819</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liang H, Song H, Zhang X, et al. Metformin attenuated sepsis-related liver injury by modulating gut microbiota. Emerg Microbes Infect. 2022;11(1):815&#x02013;28. 10.1080/22221751.2022.2045876.<pub-id pub-id-type="pmid">35191819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzanavari</surname><given-names>T</given-names></name><name><surname>Varela</surname><given-names>A</given-names></name><name><surname>Theocharis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metformin protects against infection-induced myocardial dysfunction</article-title><source>Metabolism</source><year>2016</year><volume>65</volume><issue>10</issue><fpage>1447</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2016.06.012</pub-id><pub-id pub-id-type="pmid">27621180</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Tzanavari T, Varela A, Theocharis S, et al. Metformin protects against infection-induced myocardial dysfunction. Metabolism. 2016;65(10):1447&#x02013;58. 10.1016/j.metabol.2016.06.012.<pub-id pub-id-type="pmid">27621180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Zhao H, Lyu Y, Zhai R, Sun G, Ding X. Metformin mitigates Sepsis-Related neuroinflammation via modulating gut microbiota and metabolites. Front Immunol. 2022;13. 10.3389/fimmu.2022.797312.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name></person-group><article-title>Role of IRF4 in the protection of Metformin-Mediated Sepsis myocarditis</article-title><source>Dose-Response</source><year>2019</year><volume>17</volume><issue>1</issue><fpage>1559325819827436</fpage><pub-id pub-id-type="doi">10.1177/1559325819827436</pub-id><pub-id pub-id-type="pmid">30944551</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Li M, Yu H, Wang Y, Qin L, Sun W. Role of IRF4 in the protection of Metformin-Mediated Sepsis myocarditis. Dose-Response. 2019;17(1):1559325819827436. 10.1177/1559325819827436.<pub-id pub-id-type="pmid">30944551</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Van Moorter</surname><given-names>N</given-names></name><name><surname>Tackaert</surname><given-names>T</given-names></name><name><surname>De Decker</surname><given-names>K</given-names></name><name><surname>Van Vlem</surname><given-names>B</given-names></name><name><surname>De Neve</surname><given-names>N</given-names></name></person-group><article-title>New potential for an old kid on the block: impact of premorbid Metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study</article-title><source>Endocrinol Diabetes Metab</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>e382</fpage><pub-id pub-id-type="doi">10.1002/edm2.382</pub-id><pub-id pub-id-type="pmid">36444165</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Van Moorter N, Tackaert T, De Decker K, Van Vlem B, De Neve N. New potential for an old kid on the block: impact of premorbid Metformin use on lactate kinetics, kidney injury and mortality in sepsis and septic shock, an observational study. Endocrinol Diabetes Metab. 2023;6(1):e382. 10.1002/edm2.382.<pub-id pub-id-type="pmid">36444165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Association between preadmission Metformin use and outcomes in intensive care unit patients with Sepsis and type 2 diabetes: A cohort study</article-title><source>Front Med</source><year>2021</year><volume>8</volume><fpage>640785</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.640785</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Yang Q, Zheng J, Chen W, et al. Association between preadmission Metformin use and outcomes in intensive care unit patients with Sepsis and type 2 diabetes: A cohort study. Front Med. 2021;8:640785. 10.3389/fmed.2021.640785.</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Association of preadmission Metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies</article-title><source>Crit Care</source><year>2019</year><volume>23</volume><issue>1</issue><fpage>50</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2346-4</pub-id><pub-id pub-id-type="pmid">30777119</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Liang H, Ding X, Li L, et al. Association of preadmission Metformin use and mortality in patients with sepsis and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Crit Care. 2019;23(1):50. 10.1186/s13054-019-2346-4.<pub-id pub-id-type="pmid">30777119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Doenyas-Barak</surname><given-names>K</given-names></name><name><surname>Beberashvili</surname><given-names>I</given-names></name><name><surname>Marcus</surname><given-names>R</given-names></name><name><surname>Efrati</surname><given-names>S</given-names></name></person-group><article-title>Lactic acidosis and severe septic shock in Metformin users: a cohort study</article-title><source>Crit Care</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-1180-6</pub-id><pub-id pub-id-type="pmid">26775158</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Doenyas-Barak K, Beberashvili I, Marcus R, Efrati S. Lactic acidosis and severe septic shock in Metformin users: a cohort study. Crit Care. 2016;20(1):10. 10.1186/s13054-015-1180-6.<pub-id pub-id-type="pmid">26775158</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez</surname><given-names>H</given-names></name><name><surname>Del Rio-Pertuz</surname><given-names>G</given-names></name><name><surname>Priyanka</surname><given-names>P</given-names></name><etal/></person-group><article-title>Association of Metformin use during hospitalization and mortality in critically ill adults with type 2 diabetes mellitus and Sepsis</article-title><source>Crit Care Med</source><year>2022</year><volume>50</volume><issue>6</issue><fpage>935</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000005468</pub-id><pub-id pub-id-type="pmid">35120041</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">G&#x000f3;mez H, Del Rio-Pertuz G, Priyanka P, et al. Association of Metformin use during hospitalization and mortality in critically ill adults with type 2 diabetes mellitus and Sepsis. Crit Care Med. 2022;50(6):935&#x02013;44. 10.1097/CCM.0000000000005468.<pub-id pub-id-type="pmid">35120041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>ES</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><etal/></person-group><article-title>Clinical impact of Metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus</article-title><source>Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol</source><year>2023</year><volume>42</volume><issue>12</issue><fpage>1439</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s10096-023-04679-6</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Lee JY, Kim ES, Chang E, et al. Clinical impact of Metformin exposure during Staphylococcus aureus bacteremia in patients with diabetes mellitus. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2023;42(12):1439&#x02013;47. 10.1007/s10096-023-04679-6.</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Lameire</surname><given-names>N</given-names></name><collab>KDIGO AKI Guideline Work Group</collab></person-group><article-title>Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)</article-title><source>Crit Care Lond Engl</source><year>2013</year><volume>17</volume><issue>1</issue><fpage>204</fpage><pub-id pub-id-type="doi">10.1186/cc11454</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care Lond Engl. 2013;17(1):204. 10.1186/cc11454.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>ME</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>KL</given-names></name><name><surname>MacKenzie</surname><given-names>CR</given-names></name></person-group><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source>J Chronic Dis</source><year>1987</year><volume>40</volume><issue>5</issue><fpage>373</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/0021-9681(87)90171-8</pub-id><pub-id pub-id-type="pmid">3558716</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373&#x02013;83. 10.1016/0021-9681(87)90171-8.<pub-id pub-id-type="pmid">3558716</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Foretz</surname><given-names>M</given-names></name><name><surname>Guigas</surname><given-names>B</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name></person-group><article-title>Metformin: update on mechanisms of action and repurposing potential</article-title><source>Nat Rev Endocrinol</source><year>2023</year><volume>19</volume><issue>8</issue><fpage>460</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/s41574-023-00833-4</pub-id><pub-id pub-id-type="pmid">37130947</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460&#x02013;76. 10.1038/s41574-023-00833-4.<pub-id pub-id-type="pmid">37130947</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Karise</surname><given-names>I</given-names></name><name><surname>Bargut</surname><given-names>TC</given-names></name><name><surname>del Sol</surname><given-names>M</given-names></name><name><surname>Aguila</surname><given-names>MB</given-names></name><name><surname>Mandarim-de-Lacerda</surname><given-names>CA</given-names></name></person-group><article-title>Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice</article-title><source>Biomed Pharmacother</source><year>2019</year><volume>111</volume><fpage>1156</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2019.01.021</pub-id><pub-id pub-id-type="pmid">30841429</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Karise I, Bargut TC, del Sol M, Aguila MB, Mandarim-de-Lacerda CA. Metformin enhances mitochondrial biogenesis and thermogenesis in brown adipocytes of mice. Biomed Pharmacother. 2019;111:1156&#x02013;65. 10.1016/j.biopha.2019.01.021.<pub-id pub-id-type="pmid">30841429</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhansali</surname><given-names>S</given-names></name><name><surname>Bhansali</surname><given-names>A</given-names></name><name><surname>Dhawan</surname><given-names>V</given-names></name></person-group><article-title>Metformin promotes mitophagy in mononuclear cells: a potential in vitro model for unraveling Metformin&#x02019;s mechanism of action</article-title><source>Ann N Y Acad Sci</source><year>2020</year><volume>1463</volume><issue>1</issue><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1111/nyas.14141</pub-id><pub-id pub-id-type="pmid">31225649</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bhansali S, Bhansali A, Dhawan V. Metformin promotes mitophagy in mononuclear cells: a potential in vitro model for unraveling Metformin&#x02019;s mechanism of action. Ann N Y Acad Sci. 2020;1463(1):23&#x02013;36. 10.1111/nyas.14141.<pub-id pub-id-type="pmid">31225649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>KY</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>YH</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name></person-group><article-title>Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>10</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1038/s41419-021-04235-0</pub-id><pub-id pub-id-type="pmid">33414393</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Xiong W, Sun KY, Zhu Y, Zhang X, Zhou YH, Zou X. Metformin alleviates inflammation through suppressing FASN-dependent palmitoylation of Akt. Cell Death Dis. 2021;12(10):1&#x02013;15. 10.1038/s41419-021-04235-0.<pub-id pub-id-type="pmid">33414393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rundberg Nilsson</surname><given-names>A</given-names></name><etal/></person-group><article-title>Metformin Inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation</article-title><source>Immunity</source><year>2021</year><volume>54</volume><issue>7</issue><fpage>1463</fpage><lpage>e147711</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.05.004</pub-id><pub-id pub-id-type="pmid">34115964</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin Inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463&#x02013;e147711. 10.1016/j.immuni.2021.05.004.<pub-id pub-id-type="pmid">34115964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Angriman</surname><given-names>F</given-names></name><name><surname>Lawler</surname><given-names>PR</given-names></name><name><surname>Shah</surname><given-names>BR</given-names></name><name><surname>Martin</surname><given-names>CM</given-names></name><name><surname>Scales</surname><given-names>DC</given-names></name><collab>the Sepsis Canada Network</collab></person-group><article-title>Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors: a population-based cohort study</article-title><source>Crit Care Lond Engl</source><year>2023</year><volume>27</volume><issue>1</issue><fpage>302</fpage><pub-id pub-id-type="doi">10.1186/s13054-023-04586-4</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Angriman F, Lawler PR, Shah BR, Martin CM, Scales DC, the Sepsis Canada Network. Prevalent diabetes and long-term cardiovascular outcomes in adult sepsis survivors: a population-based cohort study. Crit Care Lond Engl. 2023;27(1):302. 10.1186/s13054-023-04586-4.</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000f6;ller-Sch&#x000f6;n</surname><given-names>S</given-names></name><name><surname>Knorr</surname><given-names>M</given-names></name><name><surname>Hausding</surname><given-names>M</given-names></name><etal/></person-group><article-title>Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 Inhibition</article-title><source>Cardiovasc Res</source><year>2012</year><volume>96</volume><issue>1</issue><fpage>140</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvs246</pub-id><pub-id pub-id-type="pmid">22843705</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kr&#x000f6;ller-Sch&#x000f6;n S, Knorr M, Hausding M, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 Inhibition. Cardiovasc Res. 2012;96(1):140&#x02013;9. 10.1093/cvr/cvs246.<pub-id pub-id-type="pmid">22843705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>JF</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Clapp</surname><given-names>LH</given-names></name></person-group><article-title>Role of KATP channels in sepsis</article-title><source>Cardiovasc Res</source><year>2006</year><volume>72</volume><issue>2</issue><fpage>220</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2006.07.011</pub-id><pub-id pub-id-type="pmid">16963005</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovasc Res. 2006;72(2):220&#x02013;30. 10.1016/j.cardiores.2006.07.011.<pub-id pub-id-type="pmid">16963005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirasawa</surname><given-names>H</given-names></name><name><surname>Oda</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name></person-group><article-title>Blood glucose control in patients with severe sepsis and septic shock</article-title><source>World J Gastroenterol WJG</source><year>2009</year><volume>15</volume><issue>33</issue><fpage>4132</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.3748/wjg.15.4132</pub-id><pub-id pub-id-type="pmid">19725146</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hirasawa H, Oda S, Nakamura M. Blood glucose control in patients with severe sepsis and septic shock. World J Gastroenterol WJG. 2009;15(33):4132&#x02013;6. 10.3748/wjg.15.4132.<pub-id pub-id-type="pmid">19725146</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>